Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 20/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20611781 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20609282 | 0.91 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20611782 | 0.91 | ROCK2 (0.84) | ROCK2ROCK1 | |
| SCHEMBL30200371 | 0.91 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20608996 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL29815246 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20611755 | 0.89 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL29815836 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL20609024 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1 | |
| SCHEMBL21101410 | 0.86 | ROCK2 (0.84) | ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO LTD (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11390609-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11390609-B2 | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885 |
| US-20230030115-A1 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | ROCK1, ROCK2, RHOA | ROCK2 2/4885ROCK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.